Technical Analysis for ACRX - AcelRx Pharmaceuticals, Inc.

Grade Last Price % Change Price Change
grade F 1.8 -2.70% -0.05
ACRX closed down 2.7 percent on Friday, February 23, 2018, on 83 percent of normal volume.
5 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Flat
See historical ACRX trend table...

Date Alert Name Type % Chg
Feb 23 Wide Bands Range Expansion 0.00%
Feb 22 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -2.70%
Feb 22 Wide Bands Range Expansion -2.70%
Feb 21 50 DMA Resistance Bearish -4.26%
Feb 21 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.26%
Feb 21 Wide Bands Range Expansion -4.26%
Feb 20 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.00%
Feb 20 MACD Bullish Signal Line Cross Bullish -4.00%
Feb 20 Wide Bands Range Expansion -4.00%
Feb 16 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -5.26%

Older signals for ACRX ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
AcelRx Pharmaceuticals, Inc., a development stage specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute and breakthrough pain. The company's principal product candidate is ARX-01, a Sufentanil NanoTab PCA system, which is in Phase III clinical trials for acute post-operative pain in patients in the hospital setting. Its product candidates also comprise ARX-02, a Sufentanil NanoTab BTP management system that has completed a Phase II clinical trial for the treatment of cancer patients who suffer from breakthrough pain; and ARX-03, a Sufentanil/Triazolam NanoTab, which has completed a Phase II clinical trial to provide mild sedation, anxiety reduction, and pain relief for patients undergoing painful procedures in a physician's office. In addition, the company's product candidate under development includes ARX-04, a Sufentanil Single-Dose NanoTab for the treatment of patients with moderate-to-severe acute pain either on the battlefield or in civilian settings of trauma or injury. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.
Is ACRX a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.75
52 Week Low 1.55
Average Volume 407,009
200-Day Moving Average 2.5609
50-Day Moving Average 1.9798
20-Day Moving Average 1.8553
10-Day Moving Average 1.793
Average True Range 0.092
ADX 14.06
+DI 21.09
-DI 21.09
Chandelier Exit (Long, 3 ATRs ) 1.809
Chandelier Exit (Short, 3 ATRs ) 1.976
Upper Bollinger Band 2.0488
Lower Bollinger Band 1.6618
Percent B (%b) 0.36
BandWidth 20.85916
MACD Line -0.0526
MACD Signal Line -0.064
MACD Histogram 0.0114
Fundamentals Value
Market Cap 81.68 Million
Num Shares 45.4 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -1.64
Price-to-Sales 5.25
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.03
Resistance 3 (R3) 2.03 1.97 1.99
Resistance 2 (R2) 1.97 1.91 1.96 1.97
Resistance 1 (R1) 1.88 1.87 1.85 1.88 1.96
Pivot Point 1.82 1.82 1.80 1.81 1.82
Support 1 (S1) 1.73 1.76 1.70 1.73 1.64
Support 2 (S2) 1.67 1.72 1.66 1.63
Support 3 (S3) 1.58 1.67 1.61
Support 4 (S4) 1.58